Literature DB >> 6538459

Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.

J B Vermorken, W J van der Vijgh, I Klein, A A Hart, H E Gall, H M Pinedo.   

Abstract

Pharmacokinetic studies were performed in ten patients who received short-term (4-15-min) infusions of cisplatin. Computerized nonlinear least-squares analysis (NLIN) and an adapted curve-stripping approach (CSTRIP) were used to characterize total-platinum concentration-time curves. The overall curves showed a rapid initial phase and a prolonged terminal phase, separated by a phase with secondary peaks attributed to the existence of an enterohepatic recirculation. Up to Day 5, NLIN analysis revealed three exponential phases, with half-lives of 14.4 mins, 273.7 mins, and 5.3 days, respectively. However, a significant consistent divergence (P less than 0.005) was found between the observed and predicted curves during the intermediate phase, not justifying the use of an exponential function during this phase. The shape of the intermediate curve was strongly suggestive of a second influx in the plasma compartment, the amount of which was estimated by the CSTRIP approach (1.4% +/- 0.5% of the administered dose). Free-platinum levels declined in a biphasic manner (half-lives: 9.7 +/- 0.2 and 40.4 +/- 2.5 mins; n = 3). After administration of 100 mg/m2 of cisplatin, maximum platinum levels in rbcs ranged from 0.51 to 0.58 micrograms/ml and were reached within 90-150 mins. Thereafter, rbc platinum levels declined in a biphasic fashion, with a terminal half-life, for the interval Days 5-15, of 36-47 days. The binding of platinum to both plasma and proteins and rbcs in vitro (using patients' own blood) was slow, biphasic, and irreversible.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538459

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  39 in total

Review 1.  Role of red blood cells in pharmacokinetics of chemotherapeutic agents.

Authors:  Dirk Schrijvers
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Chemical reactivity of cisplatin bound to human plasma proteins.

Authors:  L Hegedüs; W J van der Vijgh; I Klein; S Kerpel-Fronius; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Determination of cis-diamminedichloroplatinum (II) in plasma proteins and hemoglobin of cancer patients.

Authors:  R Mustonen; P Hietanen; S Leppälä; M Takala; K Hemminki
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

4.  Comparison of cochlear cell death caused by cisplatin, alone and in combination with furosemide.

Authors:  Li Xia; Zhengnong Chen; Kaiming Su; Shankai Yin; Jian Wang
Journal:  Toxicol Pathol       Date:  2013-04-02       Impact factor: 1.902

5.  A model for ultrafilterable plasma platinum disposition in patients treated with cisplatin.

Authors:  P A Reece; I Stafford; J Russell; M Khan; P G Gill
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats.

Authors:  S Sugimoto; Y L Yamamoto; S Nagahiro; M Diksic
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers.

Authors:  Suayib Yalçin
Journal:  Gastrointest Cancer Res       Date:  2009-09

8.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

Review 9.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 10.  Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.

Authors:  Jochen Schacht; Andra E Talaska; Leonard P Rybak
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.